Takeda, Daiichi Report Strong 9-Month Profit Increases
This article was originally published in PharmAsia News
Executive Summary
Japan's biggest drug maker reported a 24.5 percent profit increase for the first nine months of its current business year, mainly because of its Actos (pioglitazone hydrochloride) diabetes drug. Takeda Pharmaceutical apparently benefited from safety concerns raised with GlaxoSmithKline's rival drug Avandia (rosiglitazone maleate) by a U.S. study last May. Daiichi Sankyo reported a 24 percent profit for the April-December period because of its high blood pressure treatment Benicar (hydrochlorothiazide). (Click here for more